Search
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawn[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965].
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedFDA approved on July 24, 2012. … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalTabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and
Clomethiazole
go.drugbank.com/drugs/DB06470InvestigationalIt is a sedative and hypnotic that is widely used in treating and preventing symptoms of acute alcohol withdrawal. … It is also used for the management of agitation, restlessness, short-term insomnia and Parkinson's disease in the elderly.
Categories: Compounds used in a research, industrial, or household settingSucrose
go.drugbank.com/drugs/DB02772ApprovedInvestigationalA nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons. It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener.
Categories: Compounds used in a research, industrial, or household settingOxogluric acid
go.drugbank.com/drugs/DB08845InvestigationalNutraceuticalOxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. … Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia,
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Synonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamideDihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.